Peptide

PE-22-28

Also known as

Mini-Spadin · PE 22-28 · PE2228 · PE-2228 · PE22-28 · Spadin-related peptide (residues 22–28) · Spadin analog PE 22-28 · GVSWGLR peptide · Gly-Val-Ser-Trp-Gly-Leu-Arg · Sortilin propeptide fragment PE 22-28 · NTSR3/Sortilin-related TREK-1 ligand (spadin-lineage)

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Mini-Spadin mood peptide	PE-22-28 is a seven-amino-acid spadin-lineage fragment studied for blocking the TREK-1 potassium channel. It differs from full-length spadin and from SSRI serotonin-reuptake drugs.
Routes and analogs differ	Nasal sprays and injections under the skin are separate experiments. Modified G/A or biotinylated research analogs are different molecules; their timing does not establish plain PE-22-28 timing.
The target and the hoped-for change	TREK-1 is a channel that influences how readily nerve cells become active. People discuss easier task-starting and clearer thinking, but those experiences do not measure new brain-cell growth.

Notes

PE-22-28, or Mini-Spadin, is an experimental mood peptide. People describe easier engagement, no change, worsening or overstimulation. Human dose, half-life and long-term safety remain unestablished.

Seven amino acids from the spadin research lineage. The sequence GVSWGLR is a shortened sortilin-propeptide fragment, not full-length spadin. Laboratory research targets TREK-1, a potassium channel influencing nerve-cell excitability. Blocking that channel differs from serotonin reuptake inhibition by SSRIs. Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity (Animal context · Accessed 2026-09-30)

Nasal sprays and SubQ injections are separate experiments. SubQ means injection beneath the skin. Some posters try nasal use after an unhelpful injected attempt, but that does not establish superior brain delivery. Modified G/A or biotinylated research analogs are also different molecules; their timing cannot be assigned to a plain PE-22-28 product. Anyone taking PE 22-28? (Community discussion · Accessed 2026-09-30)

More willingness to start and finish everyday tasks. South_Return5422 described easier task-starting, enjoyment and clearer thinking over weeks. Therapy, GLPs and later CJC/Ipamorelin complicate attribution; brain-cell growth was not measured. My PE-22-28 Experience (Community discussion · Accessed 2026-09-30)

Source context — Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity: Cells/mice; modified analogs differ; internal numeric inconsistencies; no human PK or clinical efficacy established by this paper.

Source context — Anyone taking PE 22-28?: Route/amount sometimes unstated; supplier-linked subreddit; some authors overlap other threads.

Source context — My PE-22-28 Experience: Anonymous; co-use; supplier-linked community; no causal inference.

What people notice

Easier engagement	One author described starting tasks more easily, enjoyment and clearer thinking over weeks, alongside therapy and other compounds. Brain-cell growth was not measured.
Calm, tiredness or activation	A nasal user described more positive mood and concentration but enough tiredness to prefer evening use. Others describe overstimulation, no change or worsening mood and energy.

Notes

Quieter stress or clearer thinking, sometimes with tiredness. A PeptidePathways nasal user described more positive mood and concentration, but felt tired enough to prefer evening use. Others report activation at night. Mood, energy and sleep can move in different directions rather than producing one predictable nootropic feeling. Anxiety and Depression (Community discussion · Accessed 2026-09-30)

Mood can worsen rather than lift. cyntre13 reported worsening. Mushroomgoddess69 ended two attempts by day seven because of low mood and energy. Those reports cannot establish cause but challenge a reassuring antidepressant reputation. My PE-22-28 Experience (Community discussion · Accessed 2026-09-30) · PE-22-28 experiences (Community discussion · Accessed 2026-09-30)

Nasal: several days to a week, two weeks, or still nothing. narddog019 described several days to a week; Natura91 described improvement by two weeks. Far_Fignewton reported no significant nasal change after weeks. Copied 30–60-minute clarity and 4–24-hour mood claims also appear in the anhedonia thread, but are secondhand assertions rather than a measured timeline. PE-22-28 experiences (Community discussion · Accessed 2026-09-30) · Anyone taking PE 22-28? (Community discussion · Accessed 2026-09-30)

Some report carryover into following days. narddog019 named 200–400 mcg/day intranasally with lingering overstimulation. Other accounts concern a steadier baseline across weeks, not timed coverage after one administration. The inspected reports do not establish a dependable number of hours of mood relief. PE-22-28 experiences (Community discussion · Accessed 2026-09-30)

Source context — My PE-22-28 Experience: Anonymous; co-use; supplier-linked community; no causal inference.

Source context — Anxiety and Depression: Anonymous, unverified identity and delivered amounts; atypical pain report does not establish an indication.

Source context — PE-22-28 experiences: Anonymous, unverified products; copied claims; no response-rate inference.

Source context — Anyone taking PE 22-28?: Route/amount sometimes unstated; supplier-linked subreddit; some authors overlap other threads.

Doses people talk about

Individual under-skin accounts	One author used 200 mcg each morning, with little change at 100 and irritability/restless sleep at 300. A separate 500 mcg account worsened after nearly three weeks; its frequency was unstated.
Injection charts	Separate charts name 50–200 or 250–500 mcg/day under the skin, generally once daily. Higher 600 mcg–1 mg claims and a planned 1 mg/day stack do not establish effective amounts.
Nasal user report	One spray user began with three sprays totaling 300 mcg, later six totaling 600 mcg/day. Other summaries give 100–500 mcg per administration; output and injection equivalents are unverified.
Nasal marketing amounts	Practitioner lore names 400 mcg each morning; 400 mcg per nostril instead totals 800 mcg/use. Higher tables give 1–2 mg/use once or twice daily, potentially 1–4 mg/day; these are separate marketing claims.

Notes

One SubQ account: 200 mcg daily, morning. The author reported little change at 100 mcg and irritability/restless sleep at 300 mcg. Another named 500 mcg SubQ with worsening after nearly three weeks; frequency unstated. My PE-22-28 Experience (Community discussion · Accessed 2026-09-30)

SubQ chart bands: 50–200 mcg/day versus 250–500 mcg/day. The original record separates low-dose education charts from higher clinic/vendor conventions, generally once daily. It also preserves 50–500 mcg per-administration roundups and aggressive 600 mcg–1 mg claims. A Longecity author planned 1 mg SubQ/day in a multi-compound stack; this was an intention, not a result. Mitochondrial healing and anti-inflammatory stack (Community opinion · Accessed 2026-09-30)

A nasal report: 300 mcg initially; later 600 mcg/day. Acceptable-Leg5524 described three sprays totaling 300 mcg and later six totaling 600 mcg daily. Bottle output is specific to that account. Separate preserved summaries give 100–500 mcg per administration; once- and twice-daily nasal schedules circulate without a verified conversion to SubQ amounts. Anxiety and Depression (Community discussion · Accessed 2026-09-30)

Practitioner lore: 400 mcg nasal each morning. Jay Campbell's commercial blog attributes this to Elizabeth Yurth, alongside lethargy around 800 mcg and a separate 400-mcg-per-nostril suggestion. The latter totals 800 mcg per administration. These are practitioner claims, not established depression treatment or evidence that nasal use is better. PE-22-28 Peptide: Benefits, Dosage & Side Effects (Secondhand community claim · Accessed 2026-09-30)

Higher nasal tables: 1–2 mg total per administration. The preserved marketing-heavy tables list 500 mcg–1 mg per nostril, one or two administrations daily: 1–2 mg per use, potentially 1–4 mg/day. That arithmetic is not a safety range. These claims remain separate from low-dose charts and personal reports.

Source context — My PE-22-28 Experience: Anonymous; co-use; supplier-linked community; no causal inference.

Source context — Mitochondrial healing and anti-inflammatory stack: Proposed stack only; no PE-22-28 outcome; mechanistic claims unverified.

Source context — Anxiety and Depression: Anonymous, unverified identity and delivered amounts; atypical pain report does not establish an indication.

Source context — PE-22-28 Peptide: Benefits, Dosage & Side Effects: Affiliate sales; practitioner quote relayed by author; original audio not inspected; efficacy, nasal-superiority and safety assurances not accepted.

Half-life, onset & duration

Felt onset	One under-skin author noticed changes around days 3–4 after a break and return to 200 mcg. Nasal accounts range from several days to two weeks, or no significant change after weeks.
Felt duration	No dependable number of hours. Lingering overstimulation into following days and better baseline mood across weeks are different experiences; feeling better after stopping does not measure exposure.
Half-life	No measured human value in this record. The 14–23-hour figures concern mouse behavioral effects after modified analogs, not blood clearance of plain PE-22-28.

Notes

Days 3–4 in one SubQ report; no reliable immediate kick. The author noticed effects after a two-day break and return to 200 mcg. Course onset is not absorption time. My PE-22-28 Experience (Community discussion · Accessed 2026-09-30)

Feeling better after stopping does not show persistent exposure. A Selank-blend user described remaining out of a low period after the course ended. A different person reported mood and energy returning three days after stopping an unpleasant trial. Neither observation measures peptide clearance or guarantees lasting benefit. Anyone taking pe-22-28? — Selank blend account (Personal report · Accessed 2026-09-30) · PE-22-28 experiences (Community discussion · Accessed 2026-09-30)

No measured human elimination half-life in the reviewed discussion. The near-day or 23-hour claim borrowed into community explanations comes from mouse behavior after modified analogs. It is not a blood-clearance measurement for plain PE-22-28. Once-daily habits and lingering stimulation cannot establish how quickly a human clears the peptide.

14, 21, 17 and 23 hours: modified-analog mouse half-effects. The 14–23-hour figures in Figure 7 concern modified G/A and biotinylated analogs at different mouse exposures. They describe forced-swim behavior, not plasma half-life for plain PE-22-28. Earlier spadin work was a separate molecule and experiment. Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity (Animal context · Accessed 2026-09-30)

Source context — My PE-22-28 Experience: Anonymous; co-use; supplier-linked community; no causal inference.

Source context — PE-22-28 experiences: Anonymous, unverified products; copied claims; no response-rate inference.

Source context — Anyone taking PE 22-28?: Route/amount sometimes unstated; supplier-linked subreddit; some authors overlap other threads.

Source context — Anyone taking pe-22-28? — Selank blend account: Blend attribution unresolved; supplier-linked community; cortisol assertion unverified.

Cycles people discuss

Reported calendars	One author first described about 60 days, then eight weeks on/two off. A Selank-blend account ran July–September five days/week; neither establishes a PE-22-28-alone calendar.
Chart variety	2–4-week trials, 4–8-week courses and 8–16-week charts coexist. Days-to-weeks off also circulate; no taper, post-cycle treatment or tolerance-reset schedule is established.

Notes

One author: about 60 days; later eight weeks on/two off. The clarification acknowledged unknown safety for cycling and continuous use; neither calendar is validated. My PE-22-28 Experience (Community discussion · Accessed 2026-09-30)

One nasal blend: July through September, five days/week. Candid_Worth_3629 reported weekend breaks while using PE-22-28 with Selank. A daily blend story cannot establish a calendar for PE-22-28 alone. Anyone taking pe-22-28? — Selank blend account (Personal report · Accessed 2026-09-30)

Chart lore: 2–4-week trials, 4–8-week courses, and 8–16 weeks. Longer education charts discuss optional 12–16-week extensions; days-to-weeks off and situational re-runs also circulate. Cost, uncertain chronic risks and fading perceived returns are reasons people give for breaks. There is no established taper, PCT or tolerance-reset schedule.

Source context — My PE-22-28 Experience: Anonymous; co-use; supplier-linked community; no causal inference.

Source context — Anyone taking pe-22-28? — Selank blend account: Blend attribution unresolved; supplier-linked community; cortisol assertion unverified.

Stacks

Selank blend	One user reported two sprays daily, each containing 80 mcg PE-22-28 plus 80 mcg Selank: 160 mcg of each per day. The subtle mood lift cannot be assigned to one ingredient.
Other mood/nootropic lists	Preserved examples pair 500 mcg nasal PE-22-28 with 300 mcg nasal Selank or name Semax at 600 mcg/day. DSIP, Dihexa/BPC-157, NAD+, Pinealon and SS-31 appear without a shared tested ratio.

Notes

A subtle uplift can come from a blend. The Selank-blend author described reduced misery rather than a dramatic high. Each spray reportedly held 80 mcg PE-22-28 plus 80 mcg Selank; two sprays daily supplied 160 mcg of each, a 1:1 blend. Single-agent credit and the asserted cortisol reduction remain unverified. Anyone taking pe-22-28? — Selank blend account (Personal report · Accessed 2026-09-30)

Other stack amounts describe talk, not proven synergy. Preserved examples pair 500 mcg nasal PE-22-28 with 300 mcg nasal Selank, or mention Semax at 600 mcg/day alongside PE-22-28 without its amount. DSIP, Dihexa/BPC-157, NAD+, Pinealon, SS-31 and occasional methylene-blue mentions have no shared tested ratio. Sleep, exercise and therapy can share credit.

Source context — Anyone taking pe-22-28? — Selank blend account: Blend attribution unresolved; supplier-linked community; cortisol assertion unverified.

Watch for

Mood and sleep can worsen	Some stopped because of lower mood and energy. Irritability, overstimulation, tiredness, vivid dreams and disrupted sleep appear alongside positive accounts.
Physical reactions	Reports include rapid heart rate, nausea, headache, nasal irritation and injection irritation. A headache-and-retry story does not establish harmless adaptation.
Psychiatric care and interactions	No reliable antidepressant/MAOI interaction chart or chronic-safety record is established here. Serotonin-syndrome warnings in guides are analogy, not a PE-22-28 case series; severe mood worsening needs medical attention.

Notes

Activation, tiredness and physical symptoms all appear. kayleeeeebop reported rapid heart rate and nausea after one use in the route thread. Preserved talk also includes headache, nasal sting/drip/congestion, injection irritation, lethargy, vivid dreams and sleep disruption; appetite reduction is a minor report. The earlier headache-and-retry note is not proof of harmless adaptation. Anyone taking PE 22-28? (Community discussion · Accessed 2026-09-30)

Interactions and product identity remain uncertain. Antidepressant and MAOI combinations have no reliable interaction chart here. Serotonin-syndrome language in secondary guides is precaution by analogy, not a demonstrated PE-22-28 case series. Pregnancy/breastfeeding safety, chronic psychiatric effects and claimed product purity are not established by these reports.

A research product is not a replacement for psychiatric care. The preserved community boundary includes severe depression, bipolar symptoms, psychosis and suicidal thoughts. Severe mood worsening or alarming cardiac or neurological symptoms warrant medical attention. Low microgram amounts, parent-spadin animal safety claims and favorable testimonials do not establish safety in a person.

Source context — My PE-22-28 Experience: Anonymous; co-use; supplier-linked community; no causal inference.

Source context — PE-22-28 experiences: Anonymous, unverified products; copied claims; no response-rate inference.

Source context — Anyone taking PE 22-28?: Route/amount sometimes unstated; supplier-linked subreddit; some authors overlap other threads.

Full notes

PE-22-28, or Mini-Spadin, is an experimental mood peptide. People describe easier engagement, no change, worsening or overstimulation. Human dose, half-life and long-term safety remain unestablished.

What PE-22-28 is

Seven amino acids from the spadin research lineage. The sequence GVSWGLR is a shortened sortilin-propeptide fragment, not full-length spadin. Laboratory research targets TREK-1, a potassium channel influencing nerve-cell excitability. Blocking that channel differs from serotonin reuptake inhibition by SSRIs. Animal context
Nasal sprays and SubQ injections are separate experiments. SubQ means injection beneath the skin. Some posters try nasal use after an unhelpful injected attempt, but that does not establish superior brain delivery. Modified G/A or biotinylated research analogs are also different molecules; their timing cannot be assigned to a plain PE-22-28 product. Reddit r/BodyHackGuide Community

What people hope to feel

More willingness to start and finish everyday tasks. South_Return5422 described easier task-starting, enjoyment and clearer thinking over weeks. Therapy, GLPs and later CJC/Ipamorelin complicate attribution; brain-cell growth was not measured. Reddit r/BodyHackGuide
Quieter stress or clearer thinking, sometimes with tiredness. A PeptidePathways nasal user described more positive mood and concentration, but felt tired enough to prefer evening use. Others report activation at night. Mood, energy and sleep can move in different directions rather than producing one predictable nootropic feeling. Reddit r/PeptidePathways Community

Doses people discuss

These are attributed reports and competing charts, not instructions. Micrograms (mcg) and milligrams (mg) differ by 1,000-fold; route and daily total matter.

One SubQ account: 200 mcg daily, morning. The author reported little change at 100 mcg and irritability/restless sleep at 300 mcg. Another named 500 mcg SubQ with worsening after nearly three weeks; frequency unstated. Reddit r/BodyHackGuide
SubQ chart bands: 50–200 mcg/day versus 250–500 mcg/day. The original record separates low-dose education charts from higher clinic/vendor conventions, generally once daily. It also preserves 50–500 mcg per-administration roundups and aggressive 600 mcg–1 mg claims. A Longecity author planned 1 mg SubQ/day in a multi-compound stack; this was an intention, not a result. Community Longecity
A nasal report: 300 mcg initially; later 600 mcg/day. Acceptable-Leg5524 described three sprays totaling 300 mcg and later six totaling 600 mcg daily. Bottle output is specific to that account. Separate preserved summaries give 100–500 mcg per administration; once- and twice-daily nasal schedules circulate without a verified conversion to SubQ amounts. Reddit r/PeptidePathways Community
Practitioner lore: 400 mcg nasal each morning. Jay Campbell's commercial blog attributes this to Elizabeth Yurth, alongside lethargy around 800 mcg and a separate 400-mcg-per-nostril suggestion. The latter totals 800 mcg per administration. These are practitioner claims, not established depression treatment or evidence that nasal use is better. Jay Campbell commercial biohacking blog
Higher nasal tables: 1–2 mg total per administration. The preserved marketing-heavy tables list 500 mcg–1 mg per nostril, one or two administrations daily: 1–2 mg per use, potentially 1–4 mg/day. That arithmetic is not a safety range. These claims remain separate from low-dose charts and personal reports. Community

Half-life: what the numbers mean

No measured human elimination half-life in the reviewed discussion. The near-day or 23-hour claim borrowed into community explanations comes from mouse behavior after modified analogs. It is not a blood-clearance measurement for plain PE-22-28. Once-daily habits and lingering stimulation cannot establish how quickly a human clears the peptide. Community

When people notice a change

Days 3–4 in one SubQ report; no reliable immediate kick. The author noticed effects after a two-day break and return to 200 mcg. Course onset is not absorption time. Reddit r/BodyHackGuide
Nasal: several days to a week, two weeks, or still nothing. narddog019 described several days to a week; Natura91 described improvement by two weeks. Far_Fignewton reported no significant nasal change after weeks. Copied 30–60-minute clarity and 4–24-hour mood claims also appear in the anhedonia thread, but are secondhand assertions rather than a measured timeline. Reddit r/anhedonia Reddit r/BodyHackGuide

How long a felt effect lasts

Some report carryover into following days. narddog019 named 200–400 mcg/day intranasally with lingering overstimulation. Other accounts concern a steadier baseline across weeks, not timed coverage after one administration. The inspected reports do not establish a dependable number of hours of mood relief. Reddit r/anhedonia Community
Feeling better after stopping does not show persistent exposure. A Selank-blend user described remaining out of a low period after the course ended. A different person reported mood and energy returning three days after stopping an unpleasant trial. Neither observation measures peptide clearance or guarantees lasting benefit. Personal report Reddit r/anhedonia

Courses and breaks people report

One author: about 60 days; later eight weeks on/two off. The clarification acknowledged unknown safety for cycling and continuous use; neither calendar is validated. Reddit r/BodyHackGuide
One nasal blend: July through September, five days/week. Candid_Worth_3629 reported weekend breaks while using PE-22-28 with Selank. A daily blend story cannot establish a calendar for PE-22-28 alone. Personal report
Chart lore: 2–4-week trials, 4–8-week courses, and 8–16 weeks. Longer education charts discuss optional 12–16-week extensions; days-to-weeks off and situational re-runs also circulate. Cost, uncertain chronic risks and fading perceived returns are reasons people give for breaks. There is no established taper, PCT or tolerance-reset schedule. Community

What deserves attention

Mood can worsen rather than lift. cyntre13 reported worsening. Mushroomgoddess69 ended two attempts by day seven because of low mood and energy. Those reports cannot establish cause but challenge a reassuring antidepressant reputation. Reddit r/BodyHackGuide Reddit r/anhedonia
Activation, tiredness and physical symptoms all appear. kayleeeeebop reported rapid heart rate and nausea after one use in the route thread. Preserved talk also includes headache, nasal sting/drip/congestion, injection irritation, lethargy, vivid dreams and sleep disruption; appetite reduction is a minor report. The earlier headache-and-retry note is not proof of harmless adaptation. Reddit r/BodyHackGuide Community
Interactions and product identity remain uncertain. Antidepressant and MAOI combinations have no reliable interaction chart here. Serotonin-syndrome language in secondary guides is precaution by analogy, not a demonstrated PE-22-28 case series. Pregnancy/breastfeeding safety, chronic psychiatric effects and claimed product purity are not established by these reports. Community
A research product is not a replacement for psychiatric care. The preserved community boundary includes severe depression, bipolar symptoms, psychosis and suicidal thoughts. Severe mood worsening or alarming cardiac or neurological symptoms warrant medical attention. Low microgram amounts, parent-spadin animal safety claims and favorable testimonials do not establish safety in a person. Community

What the mixed community accounts reveal

A subtle uplift can come from a blend. The Selank-blend author described reduced misery rather than a dramatic high. Each spray reportedly held 80 mcg PE-22-28 plus 80 mcg Selank; two sprays daily supplied 160 mcg of each, a 1:1 blend. Single-agent credit and the asserted cortisol reduction remain unverified. Personal report
Other stack amounts describe talk, not proven synergy. Preserved examples pair 500 mcg nasal PE-22-28 with 300 mcg nasal Selank, or mention Semax at 600 mcg/day alongside PE-22-28 without its amount. DSIP, Dihexa/BPC-157, NAD+, Pinealon, SS-31 and occasional methylene-blue mentions have no shared tested ratio. Sleep, exercise and therapy can share credit. Community
A route switch or stronger amount does not explain every result. The route thread contains early injected nonresponse, later nasal improvement and continued nonresponse. Product uncertainty and expectancy are possible explanations, not established diagnoses. Speculative neuroplasticity stacks, including the Longecity plan, should not be counted as successful PE-22-28 experiences. Reddit r/BodyHackGuide Longecity

Supporting research behind the timing story

Four-day mouse findings are not a human onset or brain-repair promise. Djillani and colleagues studied behavior, hippocampal cell proliferation and nerve-cell markers in mice. Laboratory potency and mouse findings do not provide a human dose or show that a user’s brain has repaired. Animal context
14, 21, 17 and 23 hours: modified-analog mouse half-effects. The 14–23-hour figures in Figure 7 concern modified G/A and biotinylated analogs at different mouse exposures. They describe forced-swim behavior, not plasma half-life for plain PE-22-28. Earlier spadin work was a separate molecule and experiment. Animal context